Merck and Roche sell competing pegylated introns: PegIntron and Pegasys, respectively. But their long-standing rivalry apparently pales in comparison to Merck's newer, potentially more costly competition with Vertex Pharmaceuticals
Vertex is on the verge of gaining approval for a new hepatitis C drug, Incivek, which will compete with Merck's recently approved Victrelis. The two haven't been tested head to head, but Incivek has generally posted better data. Both are used in combination with either Pegasys or PegIntron.
The partnership between Roche and Merck allows Roche to market Victrelis in combination with Pegasys and its branded generic Copegus. Merck gains an additional sales force promoting the product. There's potential for Merck to lose some PegIntron sales to Pegasys, but Roche was already dominating the market, so it isn't sacrificing much.
Roche was in a no-lose situation setting up the partnership. It's unlikely that Vertex will recommend using PegIntron. And besides, the deal isn't exclusive, so Roche could presumably set up a similar marketing partnership with Vertex, too.
In addition to this pact, Merck and Roche also plan to work on combining Victrelis and pipeline drugs of the two companies. Merck has a couple of additional hepatitis C drugs in the works, and Roche has a few as well, including RG7128, which it licensed from Pharmasset
While it's clear that the future of hepatitis C treatment involves a cocktail of drugs like those currently used for HIV, it's not clear which drugs will be part of that cocktail. Some companies like Gilead Sciences
Interested in small companies? Grab this free report from Motley Fool analysts: "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke"
Motley Fool newsletter services have recommended Vertex Pharmaceuticals, Johnson & Johnson, and Gilead Sciences and have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool's disclosure policy has a bitter rivalry with an opt-in policy at a major on-line retailer.